Preclinical Efficacy and Safety of an Oncolytic Adenovirus KD01 for the Treatment of Bladder Cancer

Preclinical Efficacy and Safety of an Oncolytic Adenovirus KD01 for the Treatment of Bladder Cancer

<b>Background</b>: While Bacillus Calmette-Guérin (BCG) remains the first-line therapy for high-risk bladder cancer, 30–40% of patients develop treatment resistance necessitating radical cystectomy, some are not suitable candidates for this procedure. This underscores the critical need f...

Full description

Saved in:
Bibliographic Details
Main Authors: Jin Guo, Shengfeng Xiong, Xinyuan Zhang, Wei Gong, Yao Si, Ding Ma, Fei Li, Yingyan Han
Format: Article
Language:English
Published: MDPI AG 2025-03-01
Series:Pharmaceuticals
Subjects:
bladder cancer
KD01
oncolytic adenovirus
cisplatin
immunogenic cell death
Online Access:https://www.mdpi.com/1424-8247/18/4/511
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items